Product Description
ENA-001, is a patent-protected new chemical entity (NCE) beginning additional clinical trials during the fourth quarter of 2021. With its novel mechanism-of-action and demonstrated safety and efficacy, it holds the potential of dramatically improving the lives of those impacted by several life threatening conditions including drug overdose, post-operative respiratory depression, and apnea of prematurity. ENA-001 will offer new treatment options for physicians, emergency responders, and care-givers addressing respiratory depression in multiple settings. (Sourced from: https://enalare.com/home/pipeline/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous,Intramuscular
FDA Designation: Orphan Drug - Apnea *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Enalare
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Depressive Disorder|Respiratory Insufficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ENA-001-109 | P1 |
Recruiting |
Respiratory Insufficiency|Depressive Disorder |
2025-11-05 |
4% |
2025-06-04 |
Primary Endpoints |
| PORD | P2 |
Not yet recruiting |
Depressive Disorder|Respiratory Insufficiency |
2026-12-15 |
2% |
2025-03-18 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments |